RxDoctor Payments Data

Rita Vieira

Nurse Practitioner · Fairhaven, MANPI 1871164616

Payments from drug & device makers

$1,264in general payments, 2019–2025

Across 58 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$715
  • Johnson & Johnson$148
  • Amgen$147
  • Novartis$50
  • E.r. Squibb & Sons, L.L.C.$49
  • Lilly USA, LLC$42
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$1,20295%
  • Education$625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,264 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,193
Medicare patients
451
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab112$908,018
RinvoqUpadacitinib74$461,903
Enbrel SureclickEtanercept48$341,455
RemicadeInfliximab40$294,430
OrenciaAbatacept/Maltose59$260,764
Xeljanz XrTofacitinib Citrate37$176,472
TremfyaGuselkumab11$173,118
Orencia ClickjectAbatacept24$128,762
Taltz AutoinjectorIxekizumab16$113,656
InflectraInfliximab-Dyyb24$105,876
OrenciaAbatacept16$87,860
OtezlaApremilast12$57,152
BenlystaBelimumab12$55,027
ProliaDenosumab27$43,218
Hydroxychloroquine Sulfate790$25,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRemicade, Tremfya$148$467,54851 claims
AbbVieRinvoq$715$461,90374 claims
E.r. Squibb & Sons, L.L.C.Orencia, Orencia$49$348,62575 claims
AmgenOtezla, Prolia$147$100,37039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Fairhaven

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →